Total medical devices industry M&A deals worth $3.3bn were announced in the US in January 2022, with Owens & Minor’s $1.6bn acquisition of Apria being the sector’s biggest investment, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 91.9% over the previous month of $40.38bn and a drop of 58.8% when compared with the last 12-month average of $7.91bn.
The US held a 98.79% share of the global medical devices industry M&A deal value that totalled $3.3bn in January 2022.
In terms of M&A deal activity, the US recorded 31 deals during January 2022, marking a decrease of 13.89% over the previous month and a rise of 29.17% over the 12-month average.
US medical devices industry M&A deals in January 2022: Top deals
The top five medical devices industry M&A deals accounted for 95.3% of the overall value during January 2022.
The combined value of the top five medical devices M&A deals stood at $3.1bn, against the overall value of $3.3bn recorded for the month.
The top five medical devices industry M&A deals of January 2022 tracked by GlobalData were:
1) Owens & Minor $1.6bn acquisition deal with Apria
2) The $623m acquisition of GeneDX by Sema4 OpCo
3) ConvaTec Group $450m acquisition deal with Triad Life Sciences
4) The $240m acquisition of MyChem by Maravai LifeSciences Holdings
5) Exact Sciences $190m acquisition deal with PreventionGenetics
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.